Ray brings the experience, knowledge and personal networks from more than 20 highly productive years in regional and global leadership positions spanning the complete value chain in the pharmaceutical and biotechnology industries. Having completed his PhD at University of Manchester, UK in 1994 and a post-doctoral fellowship at McGill University, Canada, Ray joined the Technology Access and Strategic Alliances Team at Zeneca in 1995, becoming the Team Leader only a few years later. After the merger with Astra, Ray took a global management role, in-licensing new technologies and developing molecules in oncology, cardiovascular, respiratory and inflammatory disease areas, while concurrently obtaining an MBA (with distinction) at the Manchester Business School. He then moved into business development as a Senior Analyst and then Director of Corporate Development, where he spearheaded a number of transactions and contributed to shaping AstraZeneca’s strategic roadmap, including its entry into biologics. Following a period leading regional commercial operations for AstraZeneca in 14 European countries and Russia, Ray moved to senior business development roles in the biotech sector, where he out-licensed a portfolio of meningitis B assets to Sanofi, and was involved in successfully listing Emergent Biosolutions, Inc. on NASDAQ. Ray also ran his own business (BD Solutions Limited) for five years, advising clients on corporate development and commercialisation, including as CEO of Asterion Limited, where he successfully closed deals with Genzyme Inc. and Ipsen. Ray joined Crucell NV in 2010 and was part of the team instrumental in its sale to Johnson & Johnson, for whom he orchestrated deals in infectious diseases and vaccines before becoming Executive Director of Corporate Development at Amgen in 2012. In this role, Ray closed immuno-oncology deals with Boehringer Ingelheim, negotiated international commercial deals with GSK, Mitsubishi Tanabe and Novartis, and played a key part in the acquisition of Onyx Pharmaceuticals Inc. and Dezima Pharma BV. Ray took up the role of Chief Executive Officer at e-therapeutics in April 2017.
Steve joined e-therapeutics' management team in April 2014, having previously advised the Company in its £40m fundraising in 2013. He is a Chartered Accountant. Steve acted as Interim Chief Operating Officer between July 2016 and April 2017. Prior to joining e-therapeutics, Steve worked in the UK equity market for over 20 years. During this time, he was involved primarily in research and advised on numerous flotations, acquisitions and corporate transactions. He has held various research and executive roles within UK capital market companies including Altium Capital, N+1 Singer and Peel Hunt. He co-founded Blueprint Advisors in 012.
Iain, was appointed Non-Executive Chairman of e-therapeutics plc in January 2016 and in July 2016 was appointed Interim Executive Chairman until Ray Barlow’s appointment as CEO in April 2017. Iain has over 40 years’ experience in the international life sciences and technology sectors, where he has completed multiple financing transactions, and over 25 years in cross-border management as Chairman and CEO. He has led and participated in six Initial Public Offerings (“IPOs”) and has direct experience of M&A transactions in Europe, the USA and the Pacific Rim. Currently he is Non-Executive Chairman of Redx Pharma plc (LSE) and Kazia Therapeutics Limited (ASX & NASDAQ) and was responsible for leading the turnaround of both companies before appointing new executive management. He is also a qualified Chartered Director and former Vice Chairman of the Council of Royal Holloway, London University. Previously, he has held significant roles in multi-national companies including Sandoz, Hoffman La Roche, Reed Business Publishing and Celltech Group plc. He has advised banks and private equity groups on numerous company turnarounds including, as CEO of Quadrant Healthcare (1996-2000), taking the company public and signing numerous collaborations before selling the business to Elan in 2001. As Chairman and CEO at Allergy Therapeutics (2001-2002) he restructured the company prior to its IPO and as Executive Chairman at Silence Therapeutics plc (2004-2010) he turned the business around through M&A and established numerous big pharma collaborations. As Executive Chairman at Ark Therapeutics plc (2010-2015) he successfully restructured the business and disposed of the manufacturing assets and reversed in Premier Veterinary Group.
Trevor has over 40 years’ distinguished experience in the pharmaceutical and biotechnology industries as well as in academia. He is currently a Non-Executive Director of the life sciences investment company Arix Bioscience plc. He is also Visiting Professor at King’s College, London and holds honorary degrees and Gold Medals from seven universities. Previously, Trevor held significant roles in industry including Director of Allergan Inc. from 2005 to 2015 and R&D Director of The Wellcome Foundation from 1987 to 1994, where he was responsible for the development of AZT, Zovirax, Lamictal, Malarone and other medicines. Trevor has also held a number of advisory and regulatory roles including Director General of the Association of the British Pharmaceutical Industry ("ABPI"), Board member of the European Federation of Pharmaceutical Industry Associations ("EFPIA") and the International Federation of Pharmaceutical Manufacturers Associations ("IFPMA"), a member of the UK Government regulatory agency, The Medicines Commission, a member of the UK Government Pharmaceutical Industry Ministerial Strategy Working Group on Pharmaceuticals, an adviser to the Cabinet Office on the Human Genome Project, a member of the Prime Minister’s Task Force on the Competitiveness of the Pharmaceutical Industry ("PICTF") and Chair of the Government Advisory Group on Genetics Research. He joined the e-therapeutics Board in October 2015 and chairs the Remuneration Committee.
Christine, a Chartered Accountant, has some 30 years' experience in the life sciences sector, spanning a broad range of technologies and products from genetic discovery through drug development, branded pharmaceuticals and generics and medical devices. She has served as Chief Financial Officer and Chief Operating Officer and as a Non-Executive Director in a range of public and private companies, completed several public and private financing transactions and been instrumental in completing numerous M&A and licensing transactions and business restructurings, both in the UK and internationally. Christine is currently Chief Financial Officer of Acacia Pharma Group plc and a Non-Executive Director of Fertility Focus Limited and Futurenova Limited. Previously, Christine served as Chief Financial Officer and then Non-Executive Director of AIM-listed Electrical Geodesics, Inc., which was recently acquired by Philips NV, following roles as Chief Financial Officer of Optos plc, BTG plc, Oxagen Limited and Celltech-Chiroscience Group plc having started her life-sciences career as Financial Controller of Medeva plc. She joined the board of e-therapeutics in November 2017 and chairs the Audit Committee.